Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA.
Pancreatic cancer (PC) is one of the most devastating human malignancies without effective therapies. Tumor vaccine based on RNA-transfected dendritic cells (DCs) has emerged as an alternative therapeutic approach for a variety of human cancers including advanced PC. In the present study we compared the cytotoxic T lymphocyte (CTL) responses against PC cells in vitro, which were induced by DCs co-transfected with two mRNAs of tumor associated-antigens (TAA) MUC4 and survivin, versus DCs transfected with a single mRNA encoding either MUC4 or survivin. DCs co-transfected with two TAA mRNAs were found to induce stronger CTL responses against PC target cells in vitro, compared with the DCs transfected with a single mRNA. Moreover, the antigen-specific CTL responses were MHC class I-restricted. These results provide an experimental foundation for further clinical investigations of DC vaccines encoding multiple TAA epitopes for metastatic PC.
Department of Gastroenterology, The Shenyang General Hospital of PLA, No. 83 Wenhua Road, Shenyang City, Liaoning, China.
Jiang
J
Chen
Xiao-Zhong
XZ
Guo
Hong-Yu
HY
Li
Xu
X
Liu
Li-Nan
LN
Ren
Di
D
Wang
Jia-Jun
JJ
Zhao
D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000276:immunology*; D055264:Mucin-4 / Q000235:genetics / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000276:immunology*; D000077022:Survivin; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; C524658:MUC4 protein, human; D055264:Mucin-4; D000077022:Survivin
CTL response; Cancer; Dendritic cell; MUC4; Pancreatic; Survivin; Tumor associated-antigen